PPCH News Alert Propanc Health (PPCH) 0.0047 01/09/2015 20:2
Post# of 64144
Posted On: 01/09/2015 9:24:10 PM
Propanc Health (PPCH) 0.0047 $PPCH
Bio-Tech Company with Groundbreaking Technology
M2 - Fri Jan 09, 5:39AM CST
Propanc Health Group Corp., a biopharmaceutical company organized in Melbourne, Australia, in 2007, has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasis. Targeted therapies for metastatic cancer has long been regarded as an important goal in cancer research, as metastasis is the cause of most cancer-related deaths and as no currently approved cancer therapies target metastasis.
Propanc enters into $5 million Equity Purchase Agreement with Southridge Partners
PR Newswire - Mon Sep 22, 3:01PM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA" with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms.
Propanc Stock Now DWAC/FAST Eligible
GlobeNewswire - Fri Jul 18, 3:00PM CDT
Propanc Health Group Corporation (OTCQB
PCH) ("Propanc" or "the Company" , an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients, is pleased to announce that the Depository Trust Corporation (the "DTC" has approved its common stock for DWAC/FAST transfer through the Company's Transfer Agent, V Stock, LLC. This newly approved stock transfer capability will enable Propanc's shareholders to transfer their shares of Propanc stock electronically after buying or selling on the open market, without the extra expense and delay associated with the processing and transfer of physical share certificates.
Bio-Tech Company with Groundbreaking Technology
M2 - Fri Jan 09, 5:39AM CST
Propanc Health Group Corp., a biopharmaceutical company organized in Melbourne, Australia, in 2007, has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasis. Targeted therapies for metastatic cancer has long been regarded as an important goal in cancer research, as metastasis is the cause of most cancer-related deaths and as no currently approved cancer therapies target metastasis.
Propanc enters into $5 million Equity Purchase Agreement with Southridge Partners
PR Newswire - Mon Sep 22, 3:01PM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA" with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms. Propanc Stock Now DWAC/FAST Eligible
GlobeNewswire - Fri Jul 18, 3:00PM CDT
Propanc Health Group Corporation (OTCQB
PCH) ("Propanc" or "the Company" , an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients, is pleased to announce that the Depository Trust Corporation (the "DTC" has approved its common stock for DWAC/FAST transfer through the Company's Transfer Agent, V Stock, LLC. This newly approved stock transfer capability will enable Propanc's shareholders to transfer their shares of Propanc stock electronically after buying or selling on the open market, without the extra expense and delay associated with the processing and transfer of physical share certificates. 
(0)
(0)Scroll down for more posts ▼